Combinations of everolimus with antibodies against the key immune checkpoint proteins programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) are under investigation to overcome the immunosuppressive tumor microenvironment and improve therapeutic outcomes in renal cell carcinoma.526. Here, PDCD1 is linked to neoplasm.